nodes	percent_of_prediction	percent_of_DWPC	metapath
Candesartan—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.156	0.209	CbGbCtD
Candesartan—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.108	0.146	CbGbCtD
Candesartan—CYP2C8—Progesterone—uterine cancer	0.103	0.139	CbGbCtD
Candesartan—PTGS1—Etoposide—uterine cancer	0.0799	0.108	CbGbCtD
Candesartan—CYP2C9—Progesterone—uterine cancer	0.0719	0.0968	CbGbCtD
Candesartan—ABCB1—Progesterone—uterine cancer	0.0697	0.0939	CbGbCtD
Candesartan—ABCB1—Dactinomycin—uterine cancer	0.0553	0.0745	CbGbCtD
Candesartan—CYP2C8—Etoposide—uterine cancer	0.0461	0.0621	CbGbCtD
Candesartan—ABCB1—Etoposide—uterine cancer	0.0312	0.042	CbGbCtD
Candesartan—ABCB1—Doxorubicin—uterine cancer	0.0213	0.0287	CbGbCtD
Candesartan—AGTR1—artery—uterine cancer	0.00699	0.119	CbGeAlD
Candesartan—PTGS1—oviduct—uterine cancer	0.00464	0.0788	CbGeAlD
Candesartan—AGTR1—myometrium—uterine cancer	0.00338	0.0573	CbGeAlD
Candesartan—PTGS1—artery—uterine cancer	0.00307	0.0522	CbGeAlD
Candesartan—AGTR1—epithelium—uterine cancer	0.00265	0.045	CbGeAlD
Candesartan—AGTR1—uterine cervix—uterine cancer	0.00263	0.0446	CbGeAlD
Candesartan—AGTR1—smooth muscle tissue—uterine cancer	0.00255	0.0433	CbGeAlD
Candesartan—AGTR1—decidua—uterine cancer	0.0025	0.0425	CbGeAlD
Candesartan—AGTR1—renal system—uterine cancer	0.00246	0.0417	CbGeAlD
Candesartan—AGTR1—female reproductive system—uterine cancer	0.00197	0.0334	CbGeAlD
Candesartan—AGTR1—vagina—uterine cancer	0.00178	0.0302	CbGeAlD
Candesartan—CYP2C8—renal system—uterine cancer	0.00133	0.0226	CbGeAlD
Candesartan—CYP2C8—endometrium—uterine cancer	0.00129	0.0219	CbGeAlD
Candesartan—PTGS1—epithelium—uterine cancer	0.00117	0.0198	CbGeAlD
Candesartan—PTGS1—uterine cervix—uterine cancer	0.00116	0.0196	CbGeAlD
Candesartan—AGTR1—lymph node—uterine cancer	0.00115	0.0195	CbGeAlD
Candesartan—PTGS1—smooth muscle tissue—uterine cancer	0.00112	0.0191	CbGeAlD
Candesartan—PTGS1—renal system—uterine cancer	0.00108	0.0183	CbGeAlD
Candesartan—CYP2C8—female reproductive system—uterine cancer	0.00107	0.0181	CbGeAlD
Candesartan—PTGS1—endometrium—uterine cancer	0.00105	0.0177	CbGeAlD
Candesartan—PTGS1—mammalian vulva—uterine cancer	0.00101	0.0172	CbGeAlD
Candesartan—CYP2C8—vagina—uterine cancer	0.000966	0.0164	CbGeAlD
Candesartan—PTGS1—uterus—uterine cancer	0.000963	0.0163	CbGeAlD
Candesartan—CYP2C9—female reproductive system—uterine cancer	0.000949	0.0161	CbGeAlD
Candesartan—Palpitations—Progesterone—uterine cancer	0.00092	0.00468	CcSEcCtD
Candesartan—Albuminuria—Epirubicin—uterine cancer	0.000914	0.00466	CcSEcCtD
Candesartan—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.000912	0.00465	CcSEcCtD
Candesartan—Cough—Progesterone—uterine cancer	0.000908	0.00463	CcSEcCtD
Candesartan—Cardiac failure—Etoposide—uterine cancer	0.000906	0.00461	CcSEcCtD
Candesartan—Hypertension—Progesterone—uterine cancer	0.000898	0.00458	CcSEcCtD
Candesartan—Arthralgia—Progesterone—uterine cancer	0.000886	0.00451	CcSEcCtD
Candesartan—Myalgia—Progesterone—uterine cancer	0.000886	0.00451	CcSEcCtD
Candesartan—Chest pain—Progesterone—uterine cancer	0.000886	0.00451	CcSEcCtD
Candesartan—Anxiety—Progesterone—uterine cancer	0.000883	0.0045	CcSEcCtD
Candesartan—Agranulocytosis—Dactinomycin—uterine cancer	0.000878	0.00447	CcSEcCtD
Candesartan—ABCB1—myometrium—uterine cancer	0.000878	0.0149	CbGeAlD
Candesartan—Anaemia—Medroxyprogesterone Acetate—uterine cancer	0.000872	0.00444	CcSEcCtD
Candesartan—PTGS1—female reproductive system—uterine cancer	0.000866	0.0147	CbGeAlD
Candesartan—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.000862	0.00439	CcSEcCtD
Candesartan—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.000847	0.00432	CcSEcCtD
Candesartan—Albuminuria—Doxorubicin—uterine cancer	0.000846	0.00431	CcSEcCtD
Candesartan—Hepatitis—Dactinomycin—uterine cancer	0.000845	0.0043	CcSEcCtD
Candesartan—Pharyngitis—Dactinomycin—uterine cancer	0.000839	0.00427	CcSEcCtD
Candesartan—Palpitations—Medroxyprogesterone Acetate—uterine cancer	0.000833	0.00424	CcSEcCtD
Candesartan—Tachycardia—Progesterone—uterine cancer	0.000829	0.00422	CcSEcCtD
Candesartan—Hyperhidrosis—Progesterone—uterine cancer	0.000821	0.00418	CcSEcCtD
Candesartan—Arthralgia—Medroxyprogesterone Acetate—uterine cancer	0.000803	0.00409	CcSEcCtD
Candesartan—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.000803	0.00409	CcSEcCtD
Candesartan—Myalgia—Medroxyprogesterone Acetate—uterine cancer	0.000803	0.00409	CcSEcCtD
Candesartan—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.0008	0.00408	CcSEcCtD
Candesartan—Hypotension—Progesterone—uterine cancer	0.000794	0.00404	CcSEcCtD
Candesartan—PTGS1—female gonad—uterine cancer	0.000788	0.0134	CbGeAlD
Candesartan—PTGS1—vagina—uterine cancer	0.000783	0.0133	CbGeAlD
Candesartan—Musculoskeletal discomfort—Progesterone—uterine cancer	0.000774	0.00394	CcSEcCtD
Candesartan—Paraesthesia—Progesterone—uterine cancer	0.000763	0.00388	CcSEcCtD
Candesartan—Dyspnoea—Progesterone—uterine cancer	0.000757	0.00386	CcSEcCtD
Candesartan—Somnolence—Progesterone—uterine cancer	0.000755	0.00385	CcSEcCtD
Candesartan—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.000754	0.00384	CcSEcCtD
Candesartan—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.000751	0.00383	CcSEcCtD
Candesartan—Dyspepsia—Progesterone—uterine cancer	0.000748	0.00381	CcSEcCtD
Candesartan—Sweating increased—Etoposide—uterine cancer	0.000744	0.00379	CcSEcCtD
Candesartan—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000744	0.00379	CcSEcCtD
Candesartan—Hyperuricaemia—Epirubicin—uterine cancer	0.000736	0.00375	CcSEcCtD
Candesartan—Gastrointestinal disorder—Progesterone—uterine cancer	0.000733	0.00374	CcSEcCtD
Candesartan—Fatigue—Progesterone—uterine cancer	0.000732	0.00373	CcSEcCtD
Candesartan—Blood bilirubin increased—Epirubicin—uterine cancer	0.000722	0.00368	CcSEcCtD
Candesartan—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000719	0.00366	CcSEcCtD
Candesartan—Neutropenia—Etoposide—uterine cancer	0.000714	0.00364	CcSEcCtD
Candesartan—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000701	0.00357	CcSEcCtD
Candesartan—Blood uric acid increased—Epirubicin—uterine cancer	0.000695	0.00354	CcSEcCtD
Candesartan—Gastrointestinal pain—Progesterone—uterine cancer	0.000695	0.00354	CcSEcCtD
Candesartan—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000691	0.00352	CcSEcCtD
Candesartan—ABCB1—epithelium—uterine cancer	0.000689	0.0117	CbGeAlD
Candesartan—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000686	0.0035	CcSEcCtD
Candesartan—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000684	0.00349	CcSEcCtD
Candesartan—ABCB1—uterine cervix—uterine cancer	0.000683	0.0116	CbGeAlD
Candesartan—Hyperuricaemia—Doxorubicin—uterine cancer	0.000681	0.00347	CcSEcCtD
Candesartan—Anaemia—Dactinomycin—uterine cancer	0.00068	0.00346	CcSEcCtD
Candesartan—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000677	0.00345	CcSEcCtD
Candesartan—Urticaria—Progesterone—uterine cancer	0.000675	0.00344	CcSEcCtD
Candesartan—Acute coronary syndrome—Etoposide—uterine cancer	0.000672	0.00342	CcSEcCtD
Candesartan—Body temperature increased—Progesterone—uterine cancer	0.000671	0.00342	CcSEcCtD
Candesartan—Abdominal pain—Progesterone—uterine cancer	0.000671	0.00342	CcSEcCtD
Candesartan—Hyperkalaemia—Epirubicin—uterine cancer	0.000671	0.00342	CcSEcCtD
Candesartan—Renal failure—Etoposide—uterine cancer	0.00067	0.00341	CcSEcCtD
Candesartan—Blood bilirubin increased—Doxorubicin—uterine cancer	0.000668	0.0034	CcSEcCtD
Candesartan—Myocardial infarction—Etoposide—uterine cancer	0.000668	0.0034	CcSEcCtD
Candesartan—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000664	0.00338	CcSEcCtD
Candesartan—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000664	0.00338	CcSEcCtD
Candesartan—Leukopenia—Dactinomycin—uterine cancer	0.000658	0.00335	CcSEcCtD
Candesartan—ABCB1—decidua—uterine cancer	0.000651	0.011	CbGeAlD
Candesartan—Blood urea increased—Epirubicin—uterine cancer	0.000644	0.00328	CcSEcCtD
Candesartan—Blood uric acid increased—Doxorubicin—uterine cancer	0.000643	0.00328	CcSEcCtD
Candesartan—ABCB1—renal system—uterine cancer	0.000639	0.0108	CbGeAlD
Candesartan—Agranulocytosis—Etoposide—uterine cancer	0.000636	0.00324	CcSEcCtD
Candesartan—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000629	0.00321	CcSEcCtD
Candesartan—Myalgia—Dactinomycin—uterine cancer	0.000626	0.00319	CcSEcCtD
Candesartan—Hyperkalaemia—Doxorubicin—uterine cancer	0.000621	0.00316	CcSEcCtD
Candesartan—ABCB1—endometrium—uterine cancer	0.000618	0.0105	CbGeAlD
Candesartan—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000611	0.00311	CcSEcCtD
Candesartan—Asthenia—Progesterone—uterine cancer	0.000609	0.0031	CcSEcCtD
Candesartan—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000608	0.0031	CcSEcCtD
Candesartan—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000608	0.0031	CcSEcCtD
Candesartan—Urinary tract disorder—Etoposide—uterine cancer	0.000604	0.00308	CcSEcCtD
Candesartan—Pruritus—Progesterone—uterine cancer	0.000601	0.00306	CcSEcCtD
Candesartan—Urethral disorder—Etoposide—uterine cancer	0.000599	0.00305	CcSEcCtD
Candesartan—ABCB1—mammalian vulva—uterine cancer	0.000598	0.0101	CbGeAlD
Candesartan—Blood urea increased—Doxorubicin—uterine cancer	0.000596	0.00304	CcSEcCtD
Candesartan—Thrombocytopenia—Dactinomycin—uterine cancer	0.000588	0.00299	CcSEcCtD
Candesartan—Diarrhoea—Progesterone—uterine cancer	0.000581	0.00296	CcSEcCtD
Candesartan—ABCB1—uterus—uterine cancer	0.00057	0.00966	CbGeAlD
Candesartan—Dizziness—Progesterone—uterine cancer	0.000562	0.00286	CcSEcCtD
Candesartan—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000552	0.00281	CcSEcCtD
Candesartan—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000547	0.00279	CcSEcCtD
Candesartan—Cardiac failure congestive—Epirubicin—uterine cancer	0.000546	0.00278	CcSEcCtD
Candesartan—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000544	0.00277	CcSEcCtD
Candesartan—Vomiting—Progesterone—uterine cancer	0.00054	0.00275	CcSEcCtD
Candesartan—Rash—Progesterone—uterine cancer	0.000536	0.00273	CcSEcCtD
Candesartan—Dermatitis—Progesterone—uterine cancer	0.000535	0.00273	CcSEcCtD
Candesartan—Headache—Progesterone—uterine cancer	0.000532	0.00271	CcSEcCtD
Candesartan—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000527	0.00268	CcSEcCtD
Candesartan—Renal impairment—Epirubicin—uterine cancer	0.000521	0.00265	CcSEcCtD
Candesartan—Fatigue—Dactinomycin—uterine cancer	0.000518	0.00264	CcSEcCtD
Candesartan—Back pain—Etoposide—uterine cancer	0.000515	0.00262	CcSEcCtD
Candesartan—ABCB1—female reproductive system—uterine cancer	0.000512	0.00869	CbGeAlD
Candesartan—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000509	0.00259	CcSEcCtD
Candesartan—Cardiac failure—Epirubicin—uterine cancer	0.000508	0.00259	CcSEcCtD
Candesartan—PTGS1—lymph node—uterine cancer	0.000507	0.00859	CbGeAlD
Candesartan—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000506	0.00258	CcSEcCtD
Candesartan—Nausea—Progesterone—uterine cancer	0.000504	0.00257	CcSEcCtD
Candesartan—Hyponatraemia—Epirubicin—uterine cancer	0.000498	0.00253	CcSEcCtD
Candesartan—Anaemia—Etoposide—uterine cancer	0.000492	0.00251	CcSEcCtD
Candesartan—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000491	0.0025	CcSEcCtD
Candesartan—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000489	0.00249	CcSEcCtD
Candesartan—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000485	0.00247	CcSEcCtD
Candesartan—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000485	0.00247	CcSEcCtD
Candesartan—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000482	0.00246	CcSEcCtD
Candesartan—Renal impairment—Doxorubicin—uterine cancer	0.000482	0.00245	CcSEcCtD
Candesartan—Vertigo—Etoposide—uterine cancer	0.000478	0.00244	CcSEcCtD
Candesartan—Leukopenia—Etoposide—uterine cancer	0.000477	0.00243	CcSEcCtD
Candesartan—Abdominal pain—Dactinomycin—uterine cancer	0.000475	0.00242	CcSEcCtD
Candesartan—Body temperature increased—Dactinomycin—uterine cancer	0.000475	0.00242	CcSEcCtD
Candesartan—Cardiac failure—Doxorubicin—uterine cancer	0.00047	0.00239	CcSEcCtD
Candesartan—ABCB1—female gonad—uterine cancer	0.000466	0.0079	CbGeAlD
Candesartan—Cough—Etoposide—uterine cancer	0.000465	0.00237	CcSEcCtD
Candesartan—Blood creatinine increased—Epirubicin—uterine cancer	0.000464	0.00236	CcSEcCtD
Candesartan—ABCB1—vagina—uterine cancer	0.000463	0.00786	CbGeAlD
Candesartan—Hyponatraemia—Doxorubicin—uterine cancer	0.00046	0.00234	CcSEcCtD
Candesartan—Hypertension—Etoposide—uterine cancer	0.00046	0.00234	CcSEcCtD
Candesartan—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000457	0.00233	CcSEcCtD
Candesartan—Chest pain—Etoposide—uterine cancer	0.000453	0.00231	CcSEcCtD
Candesartan—Asthenia—Dactinomycin—uterine cancer	0.000431	0.00219	CcSEcCtD
Candesartan—Blood creatinine increased—Doxorubicin—uterine cancer	0.00043	0.00219	CcSEcCtD
Candesartan—Thrombocytopenia—Etoposide—uterine cancer	0.000425	0.00217	CcSEcCtD
Candesartan—Tachycardia—Etoposide—uterine cancer	0.000424	0.00216	CcSEcCtD
Candesartan—Hyperhidrosis—Etoposide—uterine cancer	0.00042	0.00214	CcSEcCtD
Candesartan—Angina pectoris—Epirubicin—uterine cancer	0.000417	0.00213	CcSEcCtD
Candesartan—Bronchitis—Epirubicin—uterine cancer	0.000412	0.0021	CcSEcCtD
Candesartan—Diarrhoea—Dactinomycin—uterine cancer	0.000411	0.00209	CcSEcCtD
Candesartan—Hypotension—Etoposide—uterine cancer	0.000406	0.00207	CcSEcCtD
Candesartan—Neutropenia—Epirubicin—uterine cancer	0.0004	0.00204	CcSEcCtD
Candesartan—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000398	0.00203	CcSEcCtD
Candesartan—Paraesthesia—Etoposide—uterine cancer	0.00039	0.00199	CcSEcCtD
Candesartan—Dyspnoea—Etoposide—uterine cancer	0.000387	0.00197	CcSEcCtD
Candesartan—Hyperglycaemia—Epirubicin—uterine cancer	0.000386	0.00197	CcSEcCtD
Candesartan—Somnolence—Etoposide—uterine cancer	0.000386	0.00197	CcSEcCtD
Candesartan—Angina pectoris—Doxorubicin—uterine cancer	0.000386	0.00197	CcSEcCtD
Candesartan—Vomiting—Dactinomycin—uterine cancer	0.000382	0.00194	CcSEcCtD
Candesartan—Bronchitis—Doxorubicin—uterine cancer	0.000381	0.00194	CcSEcCtD
Candesartan—Rash—Dactinomycin—uterine cancer	0.000379	0.00193	CcSEcCtD
Candesartan—Renal failure—Epirubicin—uterine cancer	0.000375	0.00191	CcSEcCtD
Candesartan—Gastrointestinal disorder—Etoposide—uterine cancer	0.000375	0.00191	CcSEcCtD
Candesartan—Fatigue—Etoposide—uterine cancer	0.000375	0.00191	CcSEcCtD
Candesartan—Neutropenia—Doxorubicin—uterine cancer	0.000371	0.00189	CcSEcCtD
Candesartan—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000368	0.00188	CcSEcCtD
Candesartan—Haematuria—Epirubicin—uterine cancer	0.000364	0.00185	CcSEcCtD
Candesartan—Epistaxis—Epirubicin—uterine cancer	0.00036	0.00183	CcSEcCtD
Candesartan—Sinusitis—Epirubicin—uterine cancer	0.000358	0.00182	CcSEcCtD
Candesartan—Hyperglycaemia—Doxorubicin—uterine cancer	0.000357	0.00182	CcSEcCtD
Candesartan—Nausea—Dactinomycin—uterine cancer	0.000357	0.00182	CcSEcCtD
Candesartan—Agranulocytosis—Epirubicin—uterine cancer	0.000356	0.00182	CcSEcCtD
Candesartan—Gastrointestinal pain—Etoposide—uterine cancer	0.000355	0.00181	CcSEcCtD
Candesartan—Renal failure—Doxorubicin—uterine cancer	0.000347	0.00177	CcSEcCtD
Candesartan—Urticaria—Etoposide—uterine cancer	0.000345	0.00176	CcSEcCtD
Candesartan—Haemoglobin—Epirubicin—uterine cancer	0.000345	0.00176	CcSEcCtD
Candesartan—Rhinitis—Epirubicin—uterine cancer	0.000344	0.00175	CcSEcCtD
Candesartan—Abdominal pain—Etoposide—uterine cancer	0.000343	0.00175	CcSEcCtD
Candesartan—Body temperature increased—Etoposide—uterine cancer	0.000343	0.00175	CcSEcCtD
Candesartan—Haemorrhage—Epirubicin—uterine cancer	0.000343	0.00175	CcSEcCtD
Candesartan—Hepatitis—Epirubicin—uterine cancer	0.000343	0.00175	CcSEcCtD
Candesartan—Pharyngitis—Epirubicin—uterine cancer	0.00034	0.00173	CcSEcCtD
Candesartan—Urinary tract disorder—Epirubicin—uterine cancer	0.000339	0.00172	CcSEcCtD
Candesartan—Oedema peripheral—Epirubicin—uterine cancer	0.000338	0.00172	CcSEcCtD
Candesartan—Haematuria—Doxorubicin—uterine cancer	0.000337	0.00172	CcSEcCtD
Candesartan—Urethral disorder—Epirubicin—uterine cancer	0.000336	0.00171	CcSEcCtD
Candesartan—Epistaxis—Doxorubicin—uterine cancer	0.000333	0.0017	CcSEcCtD
Candesartan—Sinusitis—Doxorubicin—uterine cancer	0.000331	0.00169	CcSEcCtD
Candesartan—Agranulocytosis—Doxorubicin—uterine cancer	0.00033	0.00168	CcSEcCtD
Candesartan—Haemoglobin—Doxorubicin—uterine cancer	0.000319	0.00162	CcSEcCtD
Candesartan—Rhinitis—Doxorubicin—uterine cancer	0.000318	0.00162	CcSEcCtD
Candesartan—Haemorrhage—Doxorubicin—uterine cancer	0.000317	0.00162	CcSEcCtD
Candesartan—Hepatitis—Doxorubicin—uterine cancer	0.000317	0.00162	CcSEcCtD
Candesartan—Pharyngitis—Doxorubicin—uterine cancer	0.000315	0.0016	CcSEcCtD
Candesartan—Urinary tract disorder—Doxorubicin—uterine cancer	0.000313	0.0016	CcSEcCtD
Candesartan—Oedema peripheral—Doxorubicin—uterine cancer	0.000312	0.00159	CcSEcCtD
Candesartan—Asthenia—Etoposide—uterine cancer	0.000312	0.00159	CcSEcCtD
Candesartan—Urethral disorder—Doxorubicin—uterine cancer	0.000311	0.00158	CcSEcCtD
Candesartan—Pruritus—Etoposide—uterine cancer	0.000307	0.00157	CcSEcCtD
Candesartan—Mental disorder—Epirubicin—uterine cancer	0.0003	0.00153	CcSEcCtD
Candesartan—ABCB1—lymph node—uterine cancer	0.000299	0.00508	CbGeAlD
Candesartan—Malnutrition—Epirubicin—uterine cancer	0.000298	0.00152	CcSEcCtD
Candesartan—Diarrhoea—Etoposide—uterine cancer	0.000297	0.00151	CcSEcCtD
Candesartan—Back pain—Epirubicin—uterine cancer	0.000289	0.00147	CcSEcCtD
Candesartan—Dizziness—Etoposide—uterine cancer	0.000287	0.00146	CcSEcCtD
Candesartan—Mental disorder—Doxorubicin—uterine cancer	0.000278	0.00142	CcSEcCtD
Candesartan—Vomiting—Etoposide—uterine cancer	0.000276	0.00141	CcSEcCtD
Candesartan—Malnutrition—Doxorubicin—uterine cancer	0.000276	0.00141	CcSEcCtD
Candesartan—Anaemia—Epirubicin—uterine cancer	0.000276	0.0014	CcSEcCtD
Candesartan—Rash—Etoposide—uterine cancer	0.000274	0.0014	CcSEcCtD
Candesartan—Dermatitis—Etoposide—uterine cancer	0.000274	0.00139	CcSEcCtD
Candesartan—Headache—Etoposide—uterine cancer	0.000272	0.00139	CcSEcCtD
Candesartan—Vertigo—Epirubicin—uterine cancer	0.000268	0.00137	CcSEcCtD
Candesartan—Leukopenia—Epirubicin—uterine cancer	0.000267	0.00136	CcSEcCtD
Candesartan—Back pain—Doxorubicin—uterine cancer	0.000267	0.00136	CcSEcCtD
Candesartan—Palpitations—Epirubicin—uterine cancer	0.000264	0.00134	CcSEcCtD
Candesartan—Cough—Epirubicin—uterine cancer	0.00026	0.00133	CcSEcCtD
Candesartan—Nausea—Etoposide—uterine cancer	0.000258	0.00131	CcSEcCtD
Candesartan—Hypertension—Epirubicin—uterine cancer	0.000258	0.00131	CcSEcCtD
Candesartan—Anaemia—Doxorubicin—uterine cancer	0.000255	0.0013	CcSEcCtD
Candesartan—Myalgia—Epirubicin—uterine cancer	0.000254	0.00129	CcSEcCtD
Candesartan—Arthralgia—Epirubicin—uterine cancer	0.000254	0.00129	CcSEcCtD
Candesartan—Chest pain—Epirubicin—uterine cancer	0.000254	0.00129	CcSEcCtD
Candesartan—Anxiety—Epirubicin—uterine cancer	0.000253	0.00129	CcSEcCtD
Candesartan—Vertigo—Doxorubicin—uterine cancer	0.000248	0.00126	CcSEcCtD
Candesartan—Leukopenia—Doxorubicin—uterine cancer	0.000247	0.00126	CcSEcCtD
Candesartan—Palpitations—Doxorubicin—uterine cancer	0.000244	0.00124	CcSEcCtD
Candesartan—Cough—Doxorubicin—uterine cancer	0.000241	0.00123	CcSEcCtD
Candesartan—Thrombocytopenia—Epirubicin—uterine cancer	0.000238	0.00121	CcSEcCtD
Candesartan—Hypertension—Doxorubicin—uterine cancer	0.000238	0.00121	CcSEcCtD
Candesartan—Tachycardia—Epirubicin—uterine cancer	0.000238	0.00121	CcSEcCtD
Candesartan—Hyperhidrosis—Epirubicin—uterine cancer	0.000235	0.0012	CcSEcCtD
Candesartan—Arthralgia—Doxorubicin—uterine cancer	0.000235	0.0012	CcSEcCtD
Candesartan—Chest pain—Doxorubicin—uterine cancer	0.000235	0.0012	CcSEcCtD
Candesartan—Myalgia—Doxorubicin—uterine cancer	0.000235	0.0012	CcSEcCtD
Candesartan—Anxiety—Doxorubicin—uterine cancer	0.000234	0.00119	CcSEcCtD
Candesartan—Hypotension—Epirubicin—uterine cancer	0.000228	0.00116	CcSEcCtD
Candesartan—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000222	0.00113	CcSEcCtD
Candesartan—Thrombocytopenia—Doxorubicin—uterine cancer	0.000221	0.00112	CcSEcCtD
Candesartan—Tachycardia—Doxorubicin—uterine cancer	0.00022	0.00112	CcSEcCtD
Candesartan—Paraesthesia—Epirubicin—uterine cancer	0.000219	0.00111	CcSEcCtD
Candesartan—Hyperhidrosis—Doxorubicin—uterine cancer	0.000218	0.00111	CcSEcCtD
Candesartan—Dyspnoea—Epirubicin—uterine cancer	0.000217	0.00111	CcSEcCtD
Candesartan—Somnolence—Epirubicin—uterine cancer	0.000217	0.0011	CcSEcCtD
Candesartan—Dyspepsia—Epirubicin—uterine cancer	0.000214	0.00109	CcSEcCtD
Candesartan—Hypotension—Doxorubicin—uterine cancer	0.000211	0.00107	CcSEcCtD
Candesartan—Gastrointestinal disorder—Epirubicin—uterine cancer	0.00021	0.00107	CcSEcCtD
Candesartan—Fatigue—Epirubicin—uterine cancer	0.00021	0.00107	CcSEcCtD
Candesartan—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000205	0.00105	CcSEcCtD
Candesartan—Paraesthesia—Doxorubicin—uterine cancer	0.000202	0.00103	CcSEcCtD
Candesartan—Dyspnoea—Doxorubicin—uterine cancer	0.000201	0.00102	CcSEcCtD
Candesartan—Somnolence—Doxorubicin—uterine cancer	0.0002	0.00102	CcSEcCtD
Candesartan—Gastrointestinal pain—Epirubicin—uterine cancer	0.000199	0.00101	CcSEcCtD
Candesartan—Dyspepsia—Doxorubicin—uterine cancer	0.000198	0.00101	CcSEcCtD
Candesartan—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000195	0.000991	CcSEcCtD
Candesartan—Fatigue—Doxorubicin—uterine cancer	0.000194	0.00099	CcSEcCtD
Candesartan—Urticaria—Epirubicin—uterine cancer	0.000193	0.000986	CcSEcCtD
Candesartan—Body temperature increased—Epirubicin—uterine cancer	0.000193	0.000981	CcSEcCtD
Candesartan—Abdominal pain—Epirubicin—uterine cancer	0.000193	0.000981	CcSEcCtD
Candesartan—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000184	0.000939	CcSEcCtD
Candesartan—Urticaria—Doxorubicin—uterine cancer	0.000179	0.000912	CcSEcCtD
Candesartan—Abdominal pain—Doxorubicin—uterine cancer	0.000178	0.000907	CcSEcCtD
Candesartan—Body temperature increased—Doxorubicin—uterine cancer	0.000178	0.000907	CcSEcCtD
Candesartan—Asthenia—Epirubicin—uterine cancer	0.000175	0.00089	CcSEcCtD
Candesartan—Pruritus—Epirubicin—uterine cancer	0.000172	0.000878	CcSEcCtD
Candesartan—Diarrhoea—Epirubicin—uterine cancer	0.000167	0.000849	CcSEcCtD
Candesartan—Asthenia—Doxorubicin—uterine cancer	0.000162	0.000824	CcSEcCtD
Candesartan—Dizziness—Epirubicin—uterine cancer	0.000161	0.00082	CcSEcCtD
Candesartan—Pruritus—Doxorubicin—uterine cancer	0.000159	0.000812	CcSEcCtD
Candesartan—Vomiting—Epirubicin—uterine cancer	0.000155	0.000789	CcSEcCtD
Candesartan—Diarrhoea—Doxorubicin—uterine cancer	0.000154	0.000785	CcSEcCtD
Candesartan—Rash—Epirubicin—uterine cancer	0.000154	0.000782	CcSEcCtD
Candesartan—Dermatitis—Epirubicin—uterine cancer	0.000153	0.000781	CcSEcCtD
Candesartan—Headache—Epirubicin—uterine cancer	0.000153	0.000777	CcSEcCtD
Candesartan—Dizziness—Doxorubicin—uterine cancer	0.000149	0.000759	CcSEcCtD
Candesartan—Nausea—Epirubicin—uterine cancer	0.000145	0.000737	CcSEcCtD
Candesartan—Vomiting—Doxorubicin—uterine cancer	0.000143	0.00073	CcSEcCtD
Candesartan—Rash—Doxorubicin—uterine cancer	0.000142	0.000724	CcSEcCtD
Candesartan—Dermatitis—Doxorubicin—uterine cancer	0.000142	0.000723	CcSEcCtD
Candesartan—Headache—Doxorubicin—uterine cancer	0.000141	0.000719	CcSEcCtD
Candesartan—Nausea—Doxorubicin—uterine cancer	0.000134	0.000682	CcSEcCtD
Candesartan—UGT1A3—Metapathway biotransformation—AKR1B10—uterine cancer	4.99e-05	0.0225	CbGpPWpGaD
Candesartan—UGT1A3—Metapathway biotransformation—AKR1B1—uterine cancer	4.64e-05	0.0209	CbGpPWpGaD
Candesartan—PTGS1—Arachidonic acid metabolism—AKR1C3—uterine cancer	4.02e-05	0.0181	CbGpPWpGaD
Candesartan—AGTR1—Arf6 trafficking events—CDH1—uterine cancer	3.67e-05	0.0165	CbGpPWpGaD
Candesartan—UGT1A3—NRF2 pathway—NFE2L2—uterine cancer	3.62e-05	0.0163	CbGpPWpGaD
Candesartan—UGT1A3—NRF2 pathway—GPX3—uterine cancer	3.46e-05	0.0156	CbGpPWpGaD
Candesartan—UGT1A3—Metapathway biotransformation—AKR1C1—uterine cancer	3.41e-05	0.0153	CbGpPWpGaD
Candesartan—PTGS1—Overview of nanoparticle effects—CXCL8—uterine cancer	3.16e-05	0.0142	CbGpPWpGaD
Candesartan—UGT1A3—Metapathway biotransformation—GPX3—uterine cancer	2.99e-05	0.0135	CbGpPWpGaD
Candesartan—PTGS1—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	2.99e-05	0.0134	CbGpPWpGaD
Candesartan—PTGS1—Selenium Micronutrient Network—GPX3—uterine cancer	2.92e-05	0.0131	CbGpPWpGaD
Candesartan—UGT1A3—Biological oxidations—CYP11A1—uterine cancer	2.82e-05	0.0127	CbGpPWpGaD
Candesartan—UGT1A3—Metapathway biotransformation—CYP11A1—uterine cancer	2.78e-05	0.0125	CbGpPWpGaD
Candesartan—AGTR1—Arf6 trafficking events—CTNNB1—uterine cancer	2.71e-05	0.0122	CbGpPWpGaD
Candesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	2.7e-05	0.0122	CbGpPWpGaD
Candesartan—UGT1A3—Metapathway biotransformation—AKR1C3—uterine cancer	2.62e-05	0.0118	CbGpPWpGaD
Candesartan—CYP2C8—Arachidonic acid metabolism—AKR1C3—uterine cancer	2.6e-05	0.0117	CbGpPWpGaD
Candesartan—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	2.38e-05	0.0107	CbGpPWpGaD
Candesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	2.37e-05	0.0107	CbGpPWpGaD
Candesartan—CYP2C8—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	2.35e-05	0.0106	CbGpPWpGaD
Candesartan—PTGS1—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	2.2e-05	0.00989	CbGpPWpGaD
Candesartan—CYP2C9—Arachidonic acid metabolism—AKR1C3—uterine cancer	2.12e-05	0.00953	CbGpPWpGaD
Candesartan—UGT1A3—Biological oxidations—CYP19A1—uterine cancer	2.07e-05	0.00933	CbGpPWpGaD
Candesartan—UGT1A3—Metapathway biotransformation—CYP19A1—uterine cancer	2.04e-05	0.0092	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	2e-05	0.00901	CbGpPWpGaD
Candesartan—AGTR1—Allograft Rejection—CXCL8—uterine cancer	1.94e-05	0.00873	CbGpPWpGaD
Candesartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	1.94e-05	0.00872	CbGpPWpGaD
Candesartan—CYP2C8—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	1.93e-05	0.00869	CbGpPWpGaD
Candesartan—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	1.91e-05	0.00861	CbGpPWpGaD
Candesartan—CYP2C8—Metapathway biotransformation—AKR1B10—uterine cancer	1.82e-05	0.00818	CbGpPWpGaD
Candesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—uterine cancer	1.77e-05	0.00798	CbGpPWpGaD
Candesartan—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	1.75e-05	0.00788	CbGpPWpGaD
Candesartan—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	1.73e-05	0.00778	CbGpPWpGaD
Candesartan—CYP2C8—Metapathway biotransformation—AKR1B1—uterine cancer	1.69e-05	0.00761	CbGpPWpGaD
Candesartan—PTGS1—Biological oxidations—CYP11A1—uterine cancer	1.59e-05	0.00714	CbGpPWpGaD
Candesartan—AGTR1—Allograft Rejection—VEGFA—uterine cancer	1.57e-05	0.00709	CbGpPWpGaD
Candesartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	1.57e-05	0.00707	CbGpPWpGaD
Candesartan—PTGS1—Selenium Micronutrient Network—MTHFR—uterine cancer	1.5e-05	0.00675	CbGpPWpGaD
Candesartan—CYP2C9—Metapathway biotransformation—AKR1B10—uterine cancer	1.48e-05	0.00666	CbGpPWpGaD
Candesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—uterine cancer	1.45e-05	0.00652	CbGpPWpGaD
Candesartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	1.42e-05	0.00642	CbGpPWpGaD
Candesartan—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	1.42e-05	0.00639	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	1.41e-05	0.00634	CbGpPWpGaD
Candesartan—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	1.41e-05	0.00633	CbGpPWpGaD
Candesartan—CYP2C9—Metapathway biotransformation—AKR1B1—uterine cancer	1.37e-05	0.00619	CbGpPWpGaD
Candesartan—CYP2C8—Metapathway biotransformation—AKR1C1—uterine cancer	1.24e-05	0.00558	CbGpPWpGaD
Candesartan—AGTR1—Peptide ligand-binding receptors—CCL2—uterine cancer	1.22e-05	0.00547	CbGpPWpGaD
Candesartan—PTGS1—Selenium Micronutrient Network—CCL2—uterine cancer	1.17e-05	0.00528	CbGpPWpGaD
Candesartan—PTGS1—Biological oxidations—CYP19A1—uterine cancer	1.17e-05	0.00526	CbGpPWpGaD
Candesartan—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	1.16e-05	0.00521	CbGpPWpGaD
Candesartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	1.15e-05	0.0052	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	1.12e-05	0.00504	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—NDUFB11—uterine cancer	1.11e-05	0.00501	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—SRD5A2—uterine cancer	1.11e-05	0.00501	CbGpPWpGaD
Candesartan—CYP2C8—Metapathway biotransformation—GPX3—uterine cancer	1.09e-05	0.0049	CbGpPWpGaD
Candesartan—CYP2C8—Biological oxidations—CYP11A1—uterine cancer	1.02e-05	0.00461	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	1.02e-05	0.00458	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	1.02e-05	0.00458	CbGpPWpGaD
Candesartan—CYP2C8—Metapathway biotransformation—CYP11A1—uterine cancer	1.01e-05	0.00455	CbGpPWpGaD
Candesartan—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	1.01e-05	0.00454	CbGpPWpGaD
Candesartan—AGTR1—Peptide ligand-binding receptors—CXCL8—uterine cancer	9.61e-06	0.00433	CbGpPWpGaD
Candesartan—CYP2C8—Metapathway biotransformation—AKR1C3—uterine cancer	9.54e-06	0.0043	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	9.1e-06	0.0041	CbGpPWpGaD
Candesartan—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	8.86e-06	0.00399	CbGpPWpGaD
Candesartan—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	8.34e-06	0.00376	CbGpPWpGaD
Candesartan—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	8.22e-06	0.0037	CbGpPWpGaD
Candesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	8.15e-06	0.00367	CbGpPWpGaD
Candesartan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	8.14e-06	0.00367	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—AKR1B1—uterine cancer	8.05e-06	0.00362	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—STAR—uterine cancer	8.05e-06	0.00362	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—AKR1B10—uterine cancer	7.82e-06	0.00352	CbGpPWpGaD
Candesartan—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	7.77e-06	0.0035	CbGpPWpGaD
Candesartan—CYP2C8—Biological oxidations—CYP19A1—uterine cancer	7.54e-06	0.00339	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	7.47e-06	0.00336	CbGpPWpGaD
Candesartan—CYP2C8—Metapathway biotransformation—CYP19A1—uterine cancer	7.43e-06	0.00335	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	7.4e-06	0.00333	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	7.17e-06	0.00323	CbGpPWpGaD
Candesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—uterine cancer	6.98e-06	0.00314	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	6.65e-06	0.00299	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	6.58e-06	0.00296	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—STAR—uterine cancer	6.58e-06	0.00296	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—RNF43—uterine cancer	6.48e-06	0.00292	CbGpPWpGaD
Candesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	6.44e-06	0.0029	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—POLD1—uterine cancer	6.32e-06	0.00284	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—NDUFB11—uterine cancer	6.27e-06	0.00282	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—SRD5A2—uterine cancer	6.27e-06	0.00282	CbGpPWpGaD
Candesartan—AGTR1—GPCR ligand binding—CCL2—uterine cancer	6.21e-06	0.00279	CbGpPWpGaD
Candesartan—AGTR1—G alpha (q) signalling events—PIK3CA—uterine cancer	6.17e-06	0.00278	CbGpPWpGaD
Candesartan—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	6.14e-06	0.00276	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	6.09e-06	0.00274	CbGpPWpGaD
Candesartan—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	6.05e-06	0.00272	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	6.04e-06	0.00272	CbGpPWpGaD
Candesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	6.01e-06	0.00271	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—INHBA—uterine cancer	5.93e-06	0.00267	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—AKR1C1—uterine cancer	5.91e-06	0.00266	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	5.75e-06	0.00259	CbGpPWpGaD
Candesartan—ABCB1—Allograft Rejection—CXCL8—uterine cancer	5.69e-06	0.00256	CbGpPWpGaD
Candesartan—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	5.63e-06	0.00254	CbGpPWpGaD
Candesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	5.52e-06	0.00249	CbGpPWpGaD
Candesartan—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	5.45e-06	0.00245	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	5.41e-06	0.00244	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	5.35e-06	0.00241	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	5.35e-06	0.00241	CbGpPWpGaD
Candesartan—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	5.34e-06	0.0024	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—AKR1C1—uterine cancer	5.34e-06	0.0024	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—RRM2—uterine cancer	5.27e-06	0.00237	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—DCN—uterine cancer	5.11e-06	0.0023	CbGpPWpGaD
Candesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	5.11e-06	0.0023	CbGpPWpGaD
Candesartan—AGTR1—GPCR ligand binding—CXCL8—uterine cancer	4.91e-06	0.00221	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	4.83e-06	0.00217	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—CYP11A1—uterine cancer	4.82e-06	0.00217	CbGpPWpGaD
Candesartan—ABCB1—Allograft Rejection—VEGFA—uterine cancer	4.62e-06	0.00208	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—AKR1C3—uterine cancer	4.55e-06	0.00205	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—STAR—uterine cancer	4.53e-06	0.00204	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—AKR1B1—uterine cancer	4.53e-06	0.00204	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	4.48e-06	0.00202	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—AKR1C3—uterine cancer	4.11e-06	0.00185	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—SRD5A2—uterine cancer	4.05e-06	0.00182	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—NDUFB11—uterine cancer	4.05e-06	0.00182	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	4.03e-06	0.00182	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—PGR—uterine cancer	4e-06	0.0018	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.93e-06	0.00177	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	3.93e-06	0.00177	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—YWHAE—uterine cancer	3.82e-06	0.00172	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.72e-06	0.00167	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—FBXW7—uterine cancer	3.66e-06	0.00165	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—POLD1—uterine cancer	3.56e-06	0.0016	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—STK11—uterine cancer	3.54e-06	0.0016	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—CYP19A1—uterine cancer	3.54e-06	0.0016	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—NDUFB11—uterine cancer	3.53e-06	0.00159	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—SRD5A2—uterine cancer	3.53e-06	0.00159	CbGpPWpGaD
Candesartan—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	3.4e-06	0.00153	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—AKR1C1—uterine cancer	3.33e-06	0.0015	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—NDUFB11—uterine cancer	3.3e-06	0.00148	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—SRD5A2—uterine cancer	3.3e-06	0.00148	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	3.2e-06	0.00144	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—STK11—uterine cancer	3.2e-06	0.00144	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—CCL2—uterine cancer	3.19e-06	0.00143	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	3.02e-06	0.00136	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—SOCS3—uterine cancer	3e-06	0.00135	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—RRM2—uterine cancer	2.97e-06	0.00134	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	2.96e-06	0.00133	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—AKR1B1—uterine cancer	2.93e-06	0.00132	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—STAR—uterine cancer	2.93e-06	0.00132	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.89e-06	0.0013	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—DCN—uterine cancer	2.88e-06	0.0013	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CDKN2B—uterine cancer	2.87e-06	0.00129	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—IGF1R—uterine cancer	2.79e-06	0.00125	CbGpPWpGaD
Candesartan—AGTR1—GPCR downstream signaling—CXCL8—uterine cancer	2.77e-06	0.00125	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	2.74e-06	0.00123	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—CYP11A1—uterine cancer	2.71e-06	0.00122	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—MTHFR—uterine cancer	2.66e-06	0.0012	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—SMAD3—uterine cancer	2.62e-06	0.00118	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	2.59e-06	0.00117	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—AKR1C3—uterine cancer	2.56e-06	0.00115	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—AKR1B1—uterine cancer	2.55e-06	0.00115	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—STAR—uterine cancer	2.55e-06	0.00115	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.52e-06	0.00114	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—CXCL8—uterine cancer	2.52e-06	0.00113	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—FGFR2—uterine cancer	2.5e-06	0.00112	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.41e-06	0.00108	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—STAR—uterine cancer	2.38e-06	0.00107	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—AKR1B1—uterine cancer	2.38e-06	0.00107	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	2.36e-06	0.00106	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—POLD1—uterine cancer	2.3e-06	0.00103	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.28e-06	0.00103	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—AKR1C1—uterine cancer	2.15e-06	0.000968	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—ESR1—uterine cancer	2.14e-06	0.000962	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—NRAS—uterine cancer	2.02e-06	0.00091	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—POLD1—uterine cancer	2e-06	0.000902	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—STK11—uterine cancer	2e-06	0.000899	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—CYP19A1—uterine cancer	2e-06	0.000899	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.94e-06	0.000873	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—RRM2—uterine cancer	1.92e-06	0.000863	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CCL2—uterine cancer	1.88e-06	0.000847	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.87e-06	0.000844	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—AKR1C1—uterine cancer	1.87e-06	0.000843	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—POLD1—uterine cancer	1.87e-06	0.000842	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—DCN—uterine cancer	1.86e-06	0.000838	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.79e-06	0.000805	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.78e-06	0.000802	CbGpPWpGaD
Candesartan—AGTR1—GPCR downstream signaling—PIK3CA—uterine cancer	1.76e-06	0.000792	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CYP11A1—uterine cancer	1.75e-06	0.000789	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.75e-06	0.000788	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—KRAS—uterine cancer	1.74e-06	0.000783	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.72e-06	0.000776	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—RRM2—uterine cancer	1.67e-06	0.000752	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—AKR1C3—uterine cancer	1.65e-06	0.000745	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—DCN—uterine cancer	1.62e-06	0.00073	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—PIK3CA—uterine cancer	1.6e-06	0.000719	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—ERBB2—uterine cancer	1.57e-06	0.000706	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—RRM2—uterine cancer	1.56e-06	0.000702	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CYP11A1—uterine cancer	1.53e-06	0.000687	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—DCN—uterine cancer	1.51e-06	0.000682	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—MTHFR—uterine cancer	1.5e-06	0.000675	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CXCL8—uterine cancer	1.49e-06	0.00067	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—PTEN—uterine cancer	1.48e-06	0.000667	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—HRAS—uterine cancer	1.48e-06	0.000666	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.45e-06	0.000655	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CDKN1B—uterine cancer	1.45e-06	0.000654	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—AKR1C3—uterine cancer	1.44e-06	0.000649	CbGpPWpGaD
Candesartan—AGTR1—GPCR downstream signaling—AKT1—uterine cancer	1.44e-06	0.000647	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CYP11A1—uterine cancer	1.43e-06	0.000642	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—EP300—uterine cancer	1.41e-06	0.000636	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CTNNB1—uterine cancer	1.37e-06	0.000618	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.35e-06	0.000606	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—PTEN—uterine cancer	1.34e-06	0.000602	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.32e-06	0.000595	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—AKT1—uterine cancer	1.3e-06	0.000588	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—STK11—uterine cancer	1.29e-06	0.000581	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CYP19A1—uterine cancer	1.29e-06	0.000581	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—EP300—uterine cancer	1.28e-06	0.000574	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.21e-06	0.000545	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—VEGFA—uterine cancer	1.21e-06	0.000544	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—NRAS—uterine cancer	1.19e-06	0.000537	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.15e-06	0.00052	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—STK11—uterine cancer	1.12e-06	0.000506	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CYP19A1—uterine cancer	1.12e-06	0.000506	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—STK11—uterine cancer	1.05e-06	0.000472	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.05e-06	0.000472	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—PIK3CA—uterine cancer	1.04e-06	0.000471	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—KRAS—uterine cancer	1.03e-06	0.000463	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	9.85e-07	0.000443	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—MTHFR—uterine cancer	9.69e-07	0.000436	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—PIK3CA—uterine cancer	9.44e-07	0.000425	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.39e-07	0.000423	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—TP53—uterine cancer	9.13e-07	0.000411	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—HRAS—uterine cancer	8.73e-07	0.000393	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.54e-07	0.000384	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—AKT1—uterine cancer	8.54e-07	0.000384	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—MTHFR—uterine cancer	8.44e-07	0.00038	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PTEN—uterine cancer	8.34e-07	0.000376	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—EP300—uterine cancer	7.96e-07	0.000358	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—MTHFR—uterine cancer	7.88e-07	0.000355	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—AKT1—uterine cancer	7.71e-07	0.000347	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.95e-07	0.000313	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PIK3CA—uterine cancer	5.89e-07	0.000265	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PTEN—uterine cancer	5.39e-07	0.000243	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—EP300—uterine cancer	5.14e-07	0.000231	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—AKT1—uterine cancer	4.81e-07	0.000217	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PTEN—uterine cancer	4.7e-07	0.000211	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—EP300—uterine cancer	4.48e-07	0.000202	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PTEN—uterine cancer	4.39e-07	0.000198	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—EP300—uterine cancer	4.18e-07	0.000188	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PIK3CA—uterine cancer	3.8e-07	0.000171	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PIK3CA—uterine cancer	3.31e-07	0.000149	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—AKT1—uterine cancer	3.11e-07	0.00014	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PIK3CA—uterine cancer	3.09e-07	0.000139	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—AKT1—uterine cancer	2.71e-07	0.000122	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—AKT1—uterine cancer	2.53e-07	0.000114	CbGpPWpGaD
